1084 related articles for article (PubMed ID: 28275118)
1. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
2. Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases.
Rohlfing S; Aurich M; Schöning T; Ho AD; Witzens-Harig M
Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):458-63. PubMed ID: 25899891
[TBL] [Abstract][Full Text] [Related]
3. Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer.
Palmieri C; Misra V; Januszewski A; Yosef H; Ashford R; Keary I; Davidson N
Clin Breast Cancer; 2014 Apr; 14(2):85-93. PubMed ID: 24325950
[TBL] [Abstract][Full Text] [Related]
4. Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen.
Długosz-Danecka M; Gruszka AM; Szmit S; Olszanecka A; Ogórka T; Sobociński M; Jaroszyński A; Krawczyk K; Skotnicki AB; Jurczak W
Chemotherapy; 2018; 63(4):238-245. PubMed ID: 30372698
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
6. Cardiac safety of liposomal anthracyclines.
Ewer MS; Martin FJ; Henderson C; Shapiro CL; Benjamin RS; Gabizon AA
Semin Oncol; 2004 Dec; 31(6 Suppl 13):161-81. PubMed ID: 15717742
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.
Xue K; Gu JJ; Zhang Q; Liu X; Wang J; Li XQ; Luo J; Hernandez-Ilizaliturri FJ; Fernandez SF; Czuczman MS; Cao J; Hong X; Guo Y
Oncotarget; 2016 May; 7(22):32519-31. PubMed ID: 27081036
[TBL] [Abstract][Full Text] [Related]
8. Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity.
Rigacci L; Annibali O; Kovalchuk S; Bonifacio E; Pregnolato F; Angrilli F; Vitolo U; Pozzi S; Broggi S; Luminari S; Merli F; Spina M; Bolis S; Margiotta-Casaluci G; Scalzulli R; Cox C; Mamusa AM; Santoro A; Zinzani PL; Ferrari S; Gini G; Vigliotti ML; Mulè A; Flenghi L;
Hematol Oncol; 2020 Oct; 38(4):478-486. PubMed ID: 32542788
[TBL] [Abstract][Full Text] [Related]
9. Cardiac safety of liposomal anthracyclines.
Safra T
Oncologist; 2003; 8 Suppl 2():17-24. PubMed ID: 13679592
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.
Gil-Gil MJ; Bellet M; Morales S; Ojeda B; Manso L; Mesia C; Garcia-Martínez E; Martinez-Jáñez N; Melé M; Llombart A; Pernas S; Villagrasa P; Blasco C; Baselga J
Breast Cancer Res Treat; 2015 Jun; 151(3):597-606. PubMed ID: 25981896
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer.
Stavridi F; Palmieri C
Expert Rev Anticancer Ther; 2008 Dec; 8(12):1859-69. PubMed ID: 19046106
[TBL] [Abstract][Full Text] [Related]
12. Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi.
Luminari S; Viel E; Ferreri AJM; Zaja F; Chimienti E; Musuraca G; Tucci A; Balzarotti M; Tani M; Salvi F; Pesce EA; Ferrari A; Liberati AM; Spadea A; Marino D; Bruno-Ventre M; Volpetti S; Bottelli C; Ravaioli E; Merli F; Spina M
Hematol Oncol; 2018 Feb; 36(1):68-75. PubMed ID: 28524259
[TBL] [Abstract][Full Text] [Related]
13. [Early detection of the cardiotoxicity induced by chemotherapy drug through two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T].
Wang W; Kang Y; Shu XH; Shen XD; He B
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):835-840. PubMed ID: 29151290
[No Abstract] [Full Text] [Related]
14. Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors.
Ding S; Xiong S; Wang X; Zhang C; Chen S; Sun M; Wu C; Zhang X; Wang M; Wang J; Shang X
Clin Transl Oncol; 2024 Jun; 26(6):1459-1466. PubMed ID: 38329609
[TBL] [Abstract][Full Text] [Related]
15. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
Robert NJ; Vogel CL; Henderson IC; Sparano JA; Moore MR; Silverman P; Overmoyer BA; Shapiro CL; Park JW; Colbern GT; Winer EP; Gabizon AA
Semin Oncol; 2004 Dec; 31(6 Suppl 13):106-46. PubMed ID: 15717740
[TBL] [Abstract][Full Text] [Related]
16. Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Curtit E; Nouyrigat P; Dohollou N; Levy E; Lortholary A; Gligorov J; Facchini T; Jaubert D; Maille N; Pivot X; Grangé V; Cals L
Eur J Cancer; 2011 Nov; 47(16):2396-402. PubMed ID: 21920729
[TBL] [Abstract][Full Text] [Related]
17. Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders.
Szmit S; Jurczak W; Zaucha JM; Długosz-Danecka M; Sosnowska-Pasiarska B; Chmielowska E; Joks M; Drozd-Sokołowska J; Knopińska-Posłuszny W; Spychałowicz W; Kumiega B; Charliński G; Morawska M; Słomian G
Int J Cardiol; 2017 May; 235():147-153. PubMed ID: 28268088
[TBL] [Abstract][Full Text] [Related]
18. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
Ghasemi K; Vaseghi G; Mansourian M
J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
[TBL] [Abstract][Full Text] [Related]
20. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
Theodoulou M; Hudis C
Cancer; 2004 May; 100(10):2052-63. PubMed ID: 15139046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]